1046 related articles for article (PubMed ID: 35281490)
21. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology.
Rutsch A; Kantsjö JB; Ronchi F
Front Immunol; 2020; 11():604179. PubMed ID: 33362788
[TBL] [Abstract][Full Text] [Related]
22. Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome.
Bicknell B; Liebert A; Borody T; Herkes G; McLachlan C; Kiat H
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298527
[TBL] [Abstract][Full Text] [Related]
23. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer's Disease-a Critical Review.
Sochocka M; Donskow-Łysoniewska K; Diniz BS; Kurpas D; Brzozowska E; Leszek J
Mol Neurobiol; 2019 Mar; 56(3):1841-1851. PubMed ID: 29936690
[TBL] [Abstract][Full Text] [Related]
24. Interlink between the gut microbiota and inflammation in the context of oxidative stress in Alzheimer's disease progression.
Das TK; Ganesh BP
Gut Microbes; 2023; 15(1):2206504. PubMed ID: 37127846
[TBL] [Abstract][Full Text] [Related]
25. Gut-Brain Axis a Key Player to Control Gut Dysbiosis in Neurological Diseases.
Pan I; Issac PK; Rahman MM; Guru A; Arockiaraj J
Mol Neurobiol; 2023 Oct; ():. PubMed ID: 37851313
[TBL] [Abstract][Full Text] [Related]
26. The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options.
Wang Q; Luo Y; Ray Chaudhuri K; Reynolds R; Tan EK; Pettersson S
Brain; 2021 Oct; 144(9):2571-2593. PubMed ID: 33856024
[TBL] [Abstract][Full Text] [Related]
27. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration.
Solanki R; Karande A; Ranganathan P
Front Neurol; 2023; 14():1149618. PubMed ID: 37255721
[TBL] [Abstract][Full Text] [Related]
28. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
Sun MF; Shen YQ
Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
[TBL] [Abstract][Full Text] [Related]
29. The Microbiota-Gut-Brain Axis.
Cryan JF; O'Riordan KJ; Cowan CSM; Sandhu KV; Bastiaanssen TFS; Boehme M; Codagnone MG; Cussotto S; Fulling C; Golubeva AV; Guzzetta KE; Jaggar M; Long-Smith CM; Lyte JM; Martin JA; Molinero-Perez A; Moloney G; Morelli E; Morillas E; O'Connor R; Cruz-Pereira JS; Peterson VL; Rea K; Ritz NL; Sherwin E; Spichak S; Teichman EM; van de Wouw M; Ventura-Silva AP; Wallace-Fitzsimons SE; Hyland N; Clarke G; Dinan TG
Physiol Rev; 2019 Oct; 99(4):1877-2013. PubMed ID: 31460832
[TBL] [Abstract][Full Text] [Related]
30. The Role of Gut Dysbiosis in the Pathophysiology of Neuropsychiatric Disorders.
Anand N; Gorantla VR; Chidambaram SB
Cells; 2022 Dec; 12(1):. PubMed ID: 36611848
[TBL] [Abstract][Full Text] [Related]
31. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
[TBL] [Abstract][Full Text] [Related]
32. The Immunopathogenesis of Alzheimer's Disease Is Related to the Composition of Gut Microbiota.
Leblhuber F; Ehrlich D; Steiner K; Geisler S; Fuchs D; Lanser L; Kurz K
Nutrients; 2021 Jan; 13(2):. PubMed ID: 33504065
[TBL] [Abstract][Full Text] [Related]
33. Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases.
Gubert C; Kong G; Renoir T; Hannan AJ
Neurobiol Dis; 2020 Feb; 134():104621. PubMed ID: 31628992
[TBL] [Abstract][Full Text] [Related]
34. The gut microbiome and Alzheimer's disease: Complex and bidirectional interactions.
Tarawneh R; Penhos E
Neurosci Biobehav Rev; 2022 Oct; 141():104814. PubMed ID: 35934087
[TBL] [Abstract][Full Text] [Related]
35. [Relationships between microbiome and neurodegeneration].
Bang C; Heinzel S
Nervenarzt; 2023 Oct; 94(10):885-891. PubMed ID: 37672084
[TBL] [Abstract][Full Text] [Related]
36. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment.
Koszewicz M; Jaroch J; Brzecka A; Ejma M; Budrewicz S; Mikhaleva LM; Muresanu C; Schield P; Somasundaram SG; Kirkland CE; Avila-Rodriguez M; Aliev G
Pharmacol Res; 2021 Feb; 164():105277. PubMed ID: 33166735
[TBL] [Abstract][Full Text] [Related]
37. Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment.
Liu S; Gao J; Zhu M; Liu K; Zhang HL
Mol Neurobiol; 2020 Dec; 57(12):5026-5043. PubMed ID: 32829453
[TBL] [Abstract][Full Text] [Related]
38. Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders.
Wiefels MD; Furar E; Eshraghi RS; Mittal J; Memis I; Moosa M; Mittal R; Eshraghi AA
Curr Neuropharmacol; 2024; 22(1):123-139. PubMed ID: 36200211
[TBL] [Abstract][Full Text] [Related]
39. Brain-Gut-Microbiota Axis in Alzheimer's Disease.
Kowalski K; Mulak A
J Neurogastroenterol Motil; 2019 Jan; 25(1):48-60. PubMed ID: 30646475
[TBL] [Abstract][Full Text] [Related]
40. Understanding the Gut-Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders.
Zheng Y; Bonfili L; Wei T; Eleuteri AM
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
